RCS - Angle PLC - Parsortix at European breast cancer conference

AngleAnnouncement

22/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV8739Ha&default-theme=true

RNS Number : 8739H  Angle PLC  22 March 2024

 For immediate release  22 March 2024

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST
CANCER CONFERENCE

 

ANGLE presenting two posters highlighting the utility of the Company's new
Portrait+ CTC Staining Kit and Portrait HER2 assay

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce its participation at
the 14(th) European Breast Cancer  Conference (EBCC) being held in Milan,
Italy on 20 to 22 March 2024.

 

EBCC is focused on multidisciplinary, high-quality clinical and translational
research, with an emphasis on innovation and technology in the management of
breast cancer. The conference is attended by researchers, physicians, patient
advocates and industry representatives providing sales, partnership and
collaboration opportunities.

 

ANGLE is presenting two posters at the conference:

 

1.  Integrating isolation using label-independent microfluidics and advanced
staining for comprehensive Circulating Tumour Cell Analysis

 

ANGLE's Parsortix(®) system and Portrait(®)+ CTC Staining Kit together
provide an optimised, efficient, and standardised solution for the harvest and
characterisation, via immunofluorescence (IF) staining, of a diverse range of
CTC phenotypes. In the presented data, half of the CTC-positive breast cancer
patient blood samples contained only mesenchymal CTCs, while half had a
combination of both epithelial and mesenchymal CTCs. Patients with purely
mesenchymal CTCs would have been missed by epitope-dependent systems. This is
important because mesenchymal CTCs or CTCs undergoing
epithelial-to-mesenchymal transition are clinically significant, playing a
critical role in cancer progression, treatment resistance and metastasis.

 

CTC clusters harvested by the Parsortix system were observed in 75% of the
CTC-positive patients which is crucial given that CTC clusters have been shown
to have up to 100 times the increased metastatic potential compared to single
CTCs. The Parsortix cassette's unique design is suited to capturing and
harvesting clusters which is often difficult with other CTC systems.

 

The study results highlight the importance of using ANGLE's Parsortix system
combined with the Company's Portrait+ CTC Staining Kit, to enable the
isolation and analysis of a range of CTC phenotypes and CTC clusters, both of
which are important in cancer progression and metastasis.

 

2.  Interrogating HER2 status in Circulating Tumour Cells isolated using the
Parsortix(®) system from Metastatic Breast Cancer patients

 

The diagnosis and treatment of breast cancer is currently guided by the
evaluation of human epidermal growth factor receptor 2 (HER2) status in tissue
biopsies. However, a tissue biopsy is invasive, is at a single point in time
and, with little opportunity for repeat testing, can become out of date. The
longitudinal monitoring of HER2 expression from blood is possible through
minimally invasive CTC-based liquid biopsy techniques. ANGLE has developed an
IF assay for HER2 protein identification on CTCs isolated and harvested using
the Parsortix system from the peripheral blood of metastatic breast cancer
(MBC) patients.

 

Results from an in-house study in 26 patients found that CTCs overexpressing
HER2 were present at similar levels in patients that had HER2+ or HER2-
tumours by primary tissue biopsy. HER2 status of CTCs was also dynamic,
changing over time in 37% of CTC positive donors which is unsurprising given
that temporal changes in HER2 tissue status are also well documented in the
literature. One third-party study of 575 breast cancer patients similarly
found that 38% had changed HER2 status from the original primary tissue biopsy
to the metastatic tissue biopsy, at disease recurrence. These initial results
using Parsortix-based harvest of CTCs demonstrate how the HER2 status between
primary tumours and CTCs can diverge, and that analysis of HER2 expression on
CTCs has the potential to help guide clinical decision making in MBC patients,
allowing for regular monitoring and tracking of treatment and/or disease
progression.

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are delighted to have had two posters presented at the EBCC conference.
The results of these studies further demonstrate the potential utility of
ANGLE's sample-to-answer Parsortix system and Portrait imaging assays for
reliable and repeatable assessment of biomarkers in a range of solid tumours,
including breast. We look forward to discussions with translational
researchers and industry representatives at this conference to explore
opportunities for sales, collaboration, and partnerships."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK. Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKFLFLZXLEBBQ